Please login to the form below

Not currently logged in
Email:
Password:

PTC Therapeutics

This page shows the latest PTC Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne

News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics ... Pfizer still has an iron in the DMD fire, in the form of its Bamboo

Latest news

  • Spinraza keeps Biogen buoyant ahead of Alzheimer’s data Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

    On the company’s results call, analysts asked about potential competition to Spinraza from rival therapies such as oral liquid drug risdiplam (RG7916) developed by Roche and PTC Therapeutics and a

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    Duchenne UK and pharma partner pilot data-sharing HTA approach. Pfizer, Roche and PTC Therapeutics are among those participating in Project Hercules. ... The pharma partners - Roche, Sarepta Therapeutics, Solid Biosciences, Summit and Wave Life

  • FDA reviewer unimpressed with PTC’s Translarna FDA reviewer unimpressed with PTC’s Translarna

    FDA reviewer unimpressed with PTC’ s Translarna. Finds the muscular dystrophy treatment's evidence to be 'not persuasive'. ... PTC Therapeutics’Duchenne muscular dystrophy drug Translarna is up for an FDA advisory committee meeting on Thursday - but

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    Meanwhile, the CHMP also said that PTC Therapeutics has withdrawn its application to extend the indications for its Duchenne muscular dystrophy (DMD) drug Translarna (ataluren) to include patients with cystic fibrosis

  • Sarepta soars as FDA clears its muscular dystrophy drug Sarepta soars as FDA clears its muscular dystrophy drug

    candidates, including BioMarin's drisapersen and PTC Therapeutics' ataluren. ... Earlier this year, Sarepta Therapeutics told Muscular Dystrophy UK that they plan to apply to the EMA by the end of 2016," said the charity in a statement.

More from news
Approximately 8 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in the competition to hustle ahead new DMD drugs to regulators. ... This month also saw CAR-T “ wunder-kid” Juno Therapeutics

  • Pharma deals during January 2014 Pharma deals during January 2014

    Firstly, there was the acquisition of Merck's subsidiary, Sirna Therapeutics for $175m upfront in cash and equity. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    Orchard Therapeutics appoints Mark Rothera as CEO. He joins from PTC Therapeutics. ... Prior to his new role, Rothera served as chief commercial officer at PTC Therapeutics, where he helped transition the company from a privately funded, US-based R&D

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics